DIAMOND is the first national network of molecular medical imaging that integrates the main 15 leading research groups in different aspects of the field of molecular imaging in pathologies of great impact on society and the health system.

Thanks to the donation, the Childhood Cancer and Blood Disorders group at VHIR is doing research to explore the use of liquid biopsy for the prediction of the evolution of patients with this rare disease.

The research, which is part of the CRESCER project in which Vall d'Hebron participates, has 1423 pregnant women among whom two different interventions will be tested.

This is the result of a study led by the IISPV, the University Hospital Pere Mata Institute and the Vall d'Hebron Research Institute (VHIR).

The start-up Tesai Care works in developing Heecap, a non-invasive electrostimulation system to avoid atrophy to the muscles of respiration in patients on mechanical ventilation in ICUs.

Dr. Lucas Moreno is the first author of the international work that presents a series of considerations for early phase studies with the aim of accelerating the arrival of new therapies to patients with childhood cancer.

A study, in which Vall d'Hebron has participated, has analysed all the interventions of this type carried out between 2006 and 2020.

The investment will enable D-Sight to progress with the first phase of clinical validation of their drug for early-stage diabetic retinopathy and glaucoma.

The project evaluates the feasibility of implementing LOLA, an AI-based virtual medical assistant with conversational technology that provides personalized tracking to patients suffering from heart failure.

The team was born from the union of the Clinical Biochemistry and the Drug Delivery and Targeting groups with the aim of improving the diagnostic and prognostic process and developing new therapeutic strategies.

The Alberto Sols Award recognizes his contributions to diabetes research, including the description of the mechanisms of neurodegeneration in diabetic retinopathy, as well as new therapeutic strategies and early neuroprotective pathways.

The research has studied the structure and function of proteins related to this degenerative disease and their interaction with SMN2 messenger RNA (mRNA), which is key to the evolution of patients.

Vall d'Hebron participated in the study in which more than half of the patients who received treatment with bacteriophages experienced significant improvements

The Vall d'Hebron work has shown that people vaccinated with Pfizer or Moderna have specific memory T lymphocytes against SARS-CoV-2 in the lung months after vaccination.

Impulsem un cop més l’acció #CadaPacientUnaRosa en què es demana a tothom que regali roses solidàries de Vall d’Hebron a pacients. A més, es repartiran gairebé 12.000 punts de llibre entre els professionals i gaudirem d'una festa participativa.

The researcher and strategic director of the Biobank and Biomodel at Vall d'Hebron Barcelona Campus Hospital will help create guidelines to regulate the development of new therapies and technologies in this area

Representants de la Unitat de Patologia Infecciosa i Immunodeficiències de Pediatria de Vall d’Hebron i el grup de recerca d'Infecció i Immunitat al pacient pediàtric del VHIR van participar en taules rodones al congrés i van rebre premis.

La consultora sènior del Servei d'Hepatologia de l'Hospital Universitari Vall d'Hebron i investigadora principal del grup de Malalties Hepàtiques del VHIR ha rebut el premi per les seves aportacions en el de les malalties hepatiques.

Les roses tenen un valor de 8€ que es destinarà a projectes d'humanització i innovació, a projectes de recerca i a l’entitat que ha elaborat les roses: El Lloc de la Dona, creada per ajudar dones que viuen en situació d’exclusió social.

El VHIR va participar activament en l'assaig clínic d'aquesta vacuna que avaluava la seguretat, la tolerabilitat i l'eficàcia.

La recaptació del “Festival dels sentits”, que ofereix música, solidaritat i estrelles michelin a La Garrotxa seran per a projectes de recerca en càncer  del VHIR i del VHIO

The clinical trial conducted by Vall d'Hebron concludes that with a simple blood test in the second trimester, more than 90% of the women will be able to stop the treatment without negative consequences for them or their babies.

La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.

A través dels grups de recerca de Malalties Infeccioses i de Microbiologia, participem en assaigs clínics per trobar nous esquemes terapèutics per a les persones amb tuberculosi.